Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disialoganglioside GD2
- Molecular classification
- Glycosphingolipid, Ganglioside
01
Overview
Disialoganglioside GD2 (GD2) is a cell surface glycolipid antigen highly expressed on several pediatric/adult solid tumors—most notably neuroblastomas—with limited distribution on healthy tissues outside neural structures. Its unique biochemical structure makes it both biologically significant and clinically actionable as an immunotherapeutic target across multiple modalities.
- Other names
- GD2Disialo ganglioside GD2
02
Mechanism of action
Antibody-dependent cellular cytotoxicity; complement-dependent cytotoxicity; direct induction of apoptosis/necrosis; inhibition of metastatic cell adhesion/homing.
03
Biological functions
Cell proliferationCell adhesionCell motilitySignal transductionNeural tissue maintenanceImmune response modulation
04
Disease associations
CancerNeuroblastomaMelanomaRetinoblastomaEwing sarcomaOsteosarcomaSmall cell lung cancer
05
Safety considerations
On-target, off-tumor toxicity due to GD2 expression in normal tissuesInfusion reactionsNeuropathic pain
06
Interacting drugs
Dinutuximab
2 more in the full profile.
07
Biomarkers
GD2 expression level in tumor tissue
Beyond the preview
Go deeper on Disialoganglioside GD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Disialoganglioside GD2.